1. Home
  2. Medical Research
  3. Baltimore, MD
  4. Lieber Institute

Lieber Institute

Lieber Institute has an America's Best Score of 42 out of 100, based on its 2023 Form 990, below the 60-point bar to be ranked.

  • Baltimore, MD
  • Tax-exempt since 2009
  • EIN: 26-3690883
libd.org ProPublica Charity Navigator
Is this your organization? Claim it Tax filings by year Nominate
42OF 100 Not ranked Below the 60-point bar How this score is calculated

Organization summary

Lieber Institute is a 501(c)(3) organization, classified under Medical Research (NTEE H48). Contributions are tax-deductible.

855 North Wolfe Street Suite 323, Baltimore, MD 21205-1503

Among the 4 scored medical research organizations in Baltimore, Lieber Institute holds 9.1 months of operating reserves (peer median 27.1 months), runs a typical yearly deficit of 15.3% (peers: surplus of 27.2%), and has grown spending 6.6% a year (peers: grown spending 2.1% a year).

In fiscal year 2023 it reported $28,903,115 in revenue and $31,448,930 in expenses, with contributions making up 90.3% of revenue.

Work here? Claim this profile to add your mission, programs and logo.

What it does

From its own Form 990, as filed with the IRS

Mission · 2023 Form 990

The mission of the institute is to translate basic genetic and molecular mechanisms of schizophrenia and related developmental brain disorders into clinical advances that change the lives of affected individuals. It is catalyzing a new understanding of brain disease by linking advances in the construction and function of the human brain with the development of novel therapeutic strategies.

Largest programs · fiscal year 2023

  • Clinical sciences: The clinical science division investigates mechanisms of schizophrenia and related brain disorders in clinical studies and in biological material from clinical samples specifically ascertained, evaluated and managed by institute staff and through collaborations with johns hopkins university, the national institute of mental health (nimh), university of bari (italy), medical coll… Read more

    Clinical sciences: The clinical science division investigates mechanisms of schizophrenia and related brain disorders in clinical studies and in biological material from clinical samples specifically ascertained, evaluated and managed by institute staff and through collaborations with johns hopkins university, the national institute of mental health (nimh), university of bari (italy), medical college of Virginia, morgan state university and others.

    $4,645,870 spent · 17.7% of program spending
  • Basic sciences: The creation of model systems at the institute to study psychiatric illness is the major goal of the basic sciences research program. Using our unique collection of human brain material and induced pluripotent STEM cell lines, we are defining the molecular signature of disease risk. To provide the basis for therapeutic intervention we are developing new technologies using human STE… Read more

    Basic sciences: The creation of model systems at the institute to study psychiatric illness is the major goal of the basic sciences research program. Using our unique collection of human brain material and induced pluripotent STEM cell lines, we are defining the molecular signature of disease risk. To provide the basis for therapeutic intervention we are developing new technologies using human STEM cells to identify the functional consequences of genetic risk factors. The goal of these studies is the identification of therapeutic targets based on the mechanisms of disease.

    $16,070,140 spent · 61.1% of program spending
  • Drug discovery: Improved genetic understanding of diseases of brain development is revealing new drug discovery opportunities. Guided by genetics, the institute's drug discovery division is investigating new targets for psychiatric diseases, with the goal of validating innovative approaches that will lead to novel medicines for patients suffering from these conditions. The drug discovery division… Read more

    Drug discovery: Improved genetic understanding of diseases of brain development is revealing new drug discovery opportunities. Guided by genetics, the institute's drug discovery division is investigating new targets for psychiatric diseases, with the goal of validating innovative approaches that will lead to novel medicines for patients suffering from these conditions. The drug discovery division maintains a state of the art medicinal chemistry laboratory and unique capabilities in target validation.

    $5,588,288 spent · 21.2% of program spending

Where each dollar went · fiscal year 2023

Of every dollar it spent, 84¢ went to programs, 16¢ to management and 0¢ to fundraising.

  • Programs $26,304,298
  • Management $5,144,632
  • Fundraising $0

In the organization's own words to the IRS, shown for context. None of this affects the America's Best Score, and a Form 990 describes programs without measuring their results.

America's Best Score

Free assessmentMethodology
Score42 / 100
DesignationNot ranked

Score breakdown

MeasureThis organizationPoints
Operating reserves9.1 mo; 1.0 mo in cash6.4 / 25
Financial balance (median margin)−15.3%1.3 / 20
Transparency2 full 990s, latest TY202312 / 20
Program growth+6.6% / yr10.8 / 15
Track record17 years6.8 / 10
Debt load34.6% of assets5.1 / 10
Total42.3 → 42
Spending on programs
Not scored; America's Best needs 65%+
84%Meets

Compared with Baltimore peers

MeasureThis organizationPeer median
Operating reserves9.1 mo27.1 mo
Typical margin−15.3%+27.2%
Spending growth+6.6% / yr+2.1% / yr
Debt load34.6%21.1%

Peers: the 4 Baltimore medical research organizations with a score, ranked or below the bar.

Tax filings by year

Financial data extracted from the Form 990 the organization filed with the IRS for each fiscal year. Revenue lines can exceed 100% when other items, such as fundraising event costs, are netted against total revenue.

Revenue$28,903,115Fiscal year 20232022: $22,894,22220222023: $28,903,1152023
Expenses$31,448,930Fiscal year 20232022: $29,512,99820222023: $31,448,9302023
Total assets$36,656,603Fiscal year 20232022: $31,106,21020222023: $36,656,6032023
Total liabilities$12,690,938Fiscal year 20232022: $5,801,21420222023: $12,690,9382023
Fiscal year ending June 2023
Revenue$28,903,115
Expenses$31,448,930
Net income−$2,545,815
Net assets$23,965,665

Notable sources of revenue

Percent of total revenue
Contributions$26,098,672
Program services$1,749,804
Investment income$700,573
Other (net)$354,066

Assets / debt

Total assets$36,656,603
Total liabilities$12,690,938
Net assets$23,965,665

Compensation

Not in our extract for this year.

Fiscal year ending June 2022
Revenue$22,894,222
Expenses$29,512,998
Net income−$6,618,776
Net assets$25,304,996

Notable sources of revenue

Percent of total revenue
Contributions$16,080,378
Program services$2,921,001
Investment income$697,583
Other (net)$3,195,260

Assets / debt

Total assets$31,106,210
Total liabilities$5,801,214
Net assets$25,304,996

Compensation

Officers and key employees$2,342,466
Share of expenses7.9%

About this data

Figures come from IRS Form 990 filings, through the IRS Exempt Organizations Business Master File (2026-11-09) and e-filed returns. Form 990 data typically lags 12–24 months behind an organization's fiscal year. Found an error?